Haemonetics Corporation

Healthcare · Medical - Instruments & Supplies

Overall research band Above average

Quality Above average

Valuation Strong

Balance sheet Very weak

Market confirmation Exceptional

One-minute company read

What this report can tell you now

What the company does

Haemonetics Corporation is a healthcare company based in Boston, Massachusetts, specializing in medical products and solutions across three main business areas: Plasma, Blood Center, and Hospital. Its Plasma segment provides automated plasma collection systems such as NexSys PCS and PCS2, along with disposables, intravenous solutions, and donor management software like NexLynk DMS. The Blood Center division offers automated apheresis equipment under the MCS brand, disposable kits for blood collection and storage, and software solutions including SafeTrace Tx and BloodTrack for blood management. In the Hospital sector, Haemonetics supplies hemostasis analyzers such as TEG, ClotPro, and HAS, supported by TEG Manager software for remote test result access, and the Cell Saver Elite+ system for autologous blood recovery in various surgical procedures.

The current research profile is Leveraged Opportunity, with elevated leverage. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

Recent market behavior is the strongest visible confirmation. Check whether it agrees with the underlying business evidence.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC10.4%Model input; read with the evidence status and period context.

Operating margin18.1%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years7.7%Model input; read with the evidence status and period context.

FCF margin19.5%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.